Table 3. Top kinase genes overexpressed >1.7 fold in metastases in > a third of patients in all metastases compared to all primary ccRCC tumors in 35 patients from the discovery dataset.

No. of patients (%)	Genes
18 (51.4%)	ADCK1, DYRK4, PDGFRA, PRKCA, ROR2, TYRO3
17 (48.5%)	TEC, PLK4, EPHB3
16 (45.7%)	PLK1, NEK2, EPHB2, EPHA3, CKD1
15 (42.8%)	AURKA, ROS1, PHMYT1, PASK, MAPK11, Kit, BUB1B
14 (40%)	IRAK3, CHEK1, AATK
13 (37.1%)	PRKCE, CAMK4, BUB1
12 (34.2%)	PRKCQ, MAPK12, KALRN, IKBKE, FES, CDC7, BTK, BLK